HIV trial stopped early after good results
| Autor: | Alison Boulton |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Allergy
Nucleoside analogue business.industry General Engineering Lamivudine General Medicine Pharmacology medicine.disease Virology Reverse transcriptase Zidovudine Indinavir medicine General Earth and Planetary Sciences HIV Protease Inhibitor Protease inhibitor (pharmacology) business Research Article General Environmental Science medicine.drug |
| Zdroj: | BMJ. 314:695-695 |
| ISSN: | 1468-5833 0959-8138 |
| DOI: | 10.1136/bmj.314.7082.695l |
| Popis: | A United States National Institutes of Health trial of patients with advanced HIV disease has been stopped early because a combination of three drugs showed significant benefits. The US National Institute of Allergy and Infectious Diseases study known as ACTG 320 examined the safety and efficacy of adding a protease inhibitor (indinavir) to two nucleoside analogue reverse transcriptase inhibitors-zidovudine and lamivudine. … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|